-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Vaxcyte, Raises Price Target to $122

Benzinga·10/05/2026 17:28:03
Needham analyst Joseph Stringer maintains Vaxcyte (NASDAQ:PCVX) with a Buy and raises the price target from $110 to $122.